The biotech will explore the potential of BI-1808 plus Keytruda in clear cell and high-grade serous ovarian cancer subtypes.

The U.S. Food and Drug Administration’s (or FDA) approval for Keytruda on October 2, 2015, to treat patients suffering with advanced non-small cell lung cancer (or NSCLC) is considered to be a major ...

Merck (NYSE:MRK) is preparing to launch a subcutaneously delivered formulation of their blockbuster cancer medication Keytruda for patient convenience as the company approaches a steep patent cliff ...

Merck MRK announced that the FDA has approved both the intravenous (“IV”) and the subcutaneous (under the skin or SC) formulation of its blockbuster PD-L1 inhibitor, Keytruda (pembrolizumab), each in ...